{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-003637","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.912599+00:00","generated_at":"2026-06-19T09:54:07.787579+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Perspective Therapeutics Q4 revenue falls 35% to $1.84M, net loss $2.9M; merger completed","bullets":["Revenue down 35% YoY to $1.84M; prostate brachytherapy sales dropped 50% due to lost largest customer orders.","Net loss $2.9M ($0.02/share) vs $1.6M ($0.01) last year; operating expenses rose to $3.7M from $2.86M.","Gross margin plunged to 22.0% from 43.3%, driven by lower prostate sales volume.","Cash & equivalents $43.8M, no debt; stockholders' equity $55.0M.","Completed merger with Viewpoint Molecular Targeting on Feb 3; name changed to Perspective Therapeutics; ticker to CATX on Feb 21."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-003637","json":"https://secwatch.observer/filing/0001437749-23-003637.json","markdown":"https://secwatch.observer/filing/0001437749-23-003637.md","text":"https://secwatch.observer/filing/0001437749-23-003637.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/0001437749-23-003637-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/isr20230215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:54:07.787579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c797b2b229d0e2c63bfe146671102203bc72b90d","claim":"Perspective Therapeutics, Inc. reported the three months ended December 31, 2022 results: revenue $1.84 million.","evidence_excerpt":"Revenue for the three months ended December 31, 2022 decreased 35% to $1.84 million versus $2.82 million in the prior year comparable period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923003637/0001437749-23-003637-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2022"},{"label":"Revenue","value":"$1.84 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}